ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2198

How Did a Mandatory Switching Policy for Biosimilars in Canada Impact Uptake and Spending?
Abstract Number: 1516

How Disease Activity Can Affect Workability in Spondyloarthropaties: A Monocentric Cohort Analysis
Abstract Number: 1495

How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Abstract Number: 0395

How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
Abstract Number: 1028

How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA?
Abstract Number: 1497

How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab
Abstract Number: 1288

How Often Do We Provide Relevant and Patient Centric Discharge Instructions in Rheumatology? A Single Academic Center Clinic Experience
Abstract Number: 2141

How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study
Abstract Number: 0666

HRES-1/Rab4 Controls the Overexpression of CD38 and Depletion of IL-2 in CD4+ T Cells; Potential Involvement in Proinflammatory Lineage Development in SLE
Abstract Number: 0786

Humoral and T-cell Responses to SARS-CoV-2 Vaccination in Patients with Rheumatoid Arthritis
Abstract Number: 0753

Humoral Immune Response Against BNT162b2 mRNA COVID-19 Vaccine in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: A Japanese Monocentric Study
Abstract Number: 0785

Humoral Immune Responses Following Four SARS-CoV-2 Vaccine Doses or COVID-19 Infection in Patients with Immune-Mediated Inflammatory Diseases on Immunosuppressive Therapy: A Prospective Cohort Study
Abstract Number: 1604

Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthritis in a Population with Baseline High Levels of Antibodies to Citrullinated Protein Antigens and Absence of Inflammatory Arthritis: Interim Analysis of the StopRA Trial
Abstract Number: 1654

Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares
Abstract Number: 0983

Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].